SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market interest as investors monitor upcoming Binance burn events and speculate on potential supply shocks driven by on-chain activity. The community remains deeply divided, with optimistic holders aggressively buying dips in anticipation of a recovery, while critics caution against the project's historical volatility.

LUNA is the native token of the Terra blockchain, a decentralized platform designed to host applications and provide financial tools. Following a transition from Terra Classic, the new Terra chain was established through a community-led governance proposal to focus on a decentralized economy without a stablecoin. As the foundational asset of the protocol, LUNA functions as the engine for the network where value moves as users pay gas fees to interact with decentralized applications. Its primary value proposition lies in its ability to scale rewards for stakers as developer activity and transaction volumes grow within the ecosystem.  The network maintains security through a Proof of Stake system using the Tendermint consensus mechanism, where 130 independent validators compare transactions to ensure the integrity of the blockchain. Users who do not want to run their own node can delegate their tokens to these validators to help record and verify data. To ensure accountability, the protocol employs slashing, a penalty that removes a small portion of staked tokens if a validator misbehaves or goes offline.  Originally created by Terraform Labs, the project has evolved into a community-governed model where independent developer groups and users maintain the protocol. Terraform Labs currently manages a claims portal for users impacted by previous network events as part of ongoing legal and bankruptcy proceedings. The token serves multiple roles, including paying for gas fees to interact with dApps , providing voting power for governance proposals , and earning rewards through a fixed 7% annual inflation rate.

Terra 2.0

TerraClassicUSD (USTC) was originally launched as an algorithmic stablecoin within the Terra ecosystem, designed to maintain a peg to the US dollar through an automated market-Module mechanism with LUNA (now LUNC). However, following the collapse of the Terra ecosystem in May 2022, the core stabilizing mechanism was disabled, and USTC lost its peg to the US dollar.  Since then, USTC has been a freely traded digital asset, with its price determined purely by market supply and demand. It no longer functions as a stablecoin, nor does it have an active peg-maintenance mechanism.  USTC remains an integral part of the Terra Classic ecosystem, where it continues to be used for various purposes, including DeFi applications , gas fees and trading. Unlike traditional fiat-backed assets, USTC’s value fluctuates based on market conditions and community participation.

TerraClassicUSD

ProShares Trust - ProShares Ultra 7-10 Year Treasury 2x Shares

ProShares Ultra 7-10 Year Treasury

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders weigh the upcoming Goliath mainnet launch against persistent skepticism regarding its long-term utility and past price volatility. While some participants are aggressively accumulating in anticipation of institutional adoption, others remain vocal about the project's lack of confirmed commercial partnerships and recurring patterns of speculative price swings.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

The DRC-20 token DOGI is gaining significant traction as community members emphasize the growth of the Doginals ecosystem and upcoming platform developments. Investors are actively discussing the token's relationship to the Dogecoin network and its potential as a memecoin play alongside established BRC-20 standards.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is trending as investors weigh potential federal regulatory shifts impacting power pricing alongside its critical role in meeting massive electricity demand from AI data centers. Community discussions remain focused on its position as a primary beneficiary of nuclear-powered grid infrastructure, despite recent market volatility and debates over the valuation impact of proposed grid auction changes.

Hubbell, Inc. engages in the designing, manufacturing, and sale of electrical and electronic products for non-residential and residential construction, industrial, and utility applications. It operates through the Electrical Solutions and Utility Solutions segments. The Electrical Solutions segment manufactures and sells wiring and electrical, lighting fixtures, and controls for indoor and outdoor applications as well as specialty lighting and communications products. The Utility Solutions segment is involved in the design, manufacture, and sale of electrical distribution, transmission, substation, and telecommunications products. The company was founded by Harvey Hubbell II in 1888 and is headquartered in Shelton, CT.

Hubbell Inc.

Hubbell is trending as a critical pick-and-shovel play for the AI power trade, with investors highlighting its role in the data center infrastructure buildout and essential grid modernization efforts. The community is focused on the stock's strong order backlogs and consistent growth, positioning it as a structural beneficiary of the ongoing transition to AI-driven electrical demand.

Alchemy Pay

Alchemy Pay is seeing heightened community discussion driven by anticipation of its upcoming L1 blockchain mainnet and ongoing regulatory expansion, with investors actively debating its long-term potential compared to similar payment-focused tokens. While some users express frustration over stagnant price action and supply unlocking, bulls are highlighting recent partnerships and broader infrastructure development as key catalysts for future growth.

Chip

CHIP is seeing intense debate as investors weigh strong AI infrastructure narratives against concerns over insider dumping and price volatility. While some community members are betting on a recovery supported by lock-up periods and potential institutional partnerships, others remain skeptical, framing the recent price action as a classic pump-and-dump cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx Announces Acceptance of Compliance Plan by NYSE American VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire HENDERSON, Nev., April 23, 2026 HENDERSON, Nev...

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients

Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...

VolitionRx Reports Over 95% Early Cancer Detection in Breakthrough Liquid Biopsy Study

VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.

<ul class="summary-bullets"><li>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples.</li><li>Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%.</li><li>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells.</li></ul>VolitionRx (VNRX) shares ripped more than 34% in Wednesday’s pre-market trade&nbsp;before paring gains to hover 16% higher in the opening trade after the company announced proof-of-concept data from a blinded validation cohort for the detection of cancer.The company said that it has developed a new liquid biopsy method, and during a blind validation cohort, it achieved over 95% sensitivity for stage I &amp; II cancers with 95% specificity.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VNRX">Volition</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Detection Rates Across Cancer Stages</h2>Volition stated in its announcement that the detection rate for stage I cancer was 94%, with its Capture-Seq method detecting in 17 of 18 samples. Its detection rate for stage II cancer stood at 96%, stage III cancer at 100%, and stage IV cancer at 91%."We are now releasing the data from a blinded validation cohort of 81 subjects and are extremely encouraged by the results, particularly in early-stage cancer detection,” said Volition’s Chief Scientific Officer, Jake Micallef.The company’s Chief Commercial Officer, Gael Forterre, said that this technology represents a Total Addressable Market of nearly $23 billion for human Multi-Cancer Early Detection (MCED) tests, and $13 billion for Minimal Residual Disease (MRD) tests on an annualized basis.“We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible,” Forterre added.<h2 class="st-heading-2">What Is Capture-Seq?</h2>Volition stated that its Capture-Seq method overcomes the hurdles in the liquid biopsy space, where the vast majority of circulating DNA in blood plasma samples comes from healthy cells rather than cancer cells. This makes it hard to detect the disease.The company says its method solves this problem, producing more than 99% pure cancer-derived plasma DNA sequence sets for liquid biopsy. This filters out the noise and improves detection accuracy.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> is down 23% year-to-date and 63% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 15% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-tanks-anavex-withdraws-alzheimers-drug-blarcamesine-eu/cZ3YF8WRISf">AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

Equity

Volition Announces Detection of Over 95% of Early-Stage Cancers

Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...

<ul class="summary-bullets"><li>The company submitted an updated manuscript detailing a new two-step method to remove nearly all non-cancer DNA.</li><li>Early results showed no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort.</li><li>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method for cancer detection.</li></ul>Shares of VolitionRx (VNRX) gave up a part of its pre-market gains to trade 30% higher on Wednesday after the diagnostics company unveiled what it called a potential breakthrough in cancer detection. The company said it was successful in isolating more than 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients.<a href="https://stocktwits.com/symbol/VNRX">VNRX stock</a> breached its 100-day moving average (100-DMA) for the first time since Oct. 8, 2025.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=AMEX%3AVNRX"><img src="https://news.stocktwits-cdn.com/VNRX_jpg_e886d96646.webp" alt="VNRX.jpg"></a>Source: TradingViewThe company submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA. This addresses a key challenge in liquid biopsy, where most circulating DNA typically comes from healthy cells.“Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA,” said Jake Micallef, Chief Scientific Officer of Volition.“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years,” Micallef added.The early results are encouraging, with no false positives and all cancers detected in the first group, along with strong validation in a second blinded cohort, VolitionRx said. The company is now working on further testing in early-stage cancers.<h2 class="st-heading-2">VolitionRx’s Capture-Seq Method for Cancer Detection</h2>VolitionRx published a research paper in December 2025, that highlighted its Capture-Seq method and novel biomarkers for cancer detection. The technology enables accurate and potentially low-cost testing across multiple cancers.&nbsp;It works by enriching ultrashort DNA fragments in blood, achieving a 180-fold increase in detection sensitivity. This approach focuses on DNA within chromosome fragments, unlike traditional methods that analyze extracted DNA.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits completely flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.Despite shedding gains, retail chatter remained primarily bullish, with one user asking for patience.<stembedurl>https://stocktwits.com/SuellenD/message/647851536</stembedurl>Another user said buy the dip.<stembedurl>https://stocktwits.com/SuellenD/message/647840635</stembedurl>Year-to-date, the stock has shed around 8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Is VNRX Stock Soaring Over 30% Today?

The company said it can isolate pure tumor DNA from blood, which potentially solves a key bottleneck in liquid biopsy.

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating...

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Current Price	$2.43
Prev Close	$2.62
Open	$2.63
Dividend Yield	0.00%
50-Day Moving Average	$3.64
Beta	0.40
Avg. Volume	201,790.10
PE Ratio	-0.56

52-Week High	$18.80
52-Week Low	$2.41
Market Capitalization	$19.26M
EPS (Annual)	-$4.37
Price to Book	-0.45
Revenue Per Employee	$23,031.79

VNRX
VolitionRX Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VNRX News

VNRXVolitionRX Ltd